T. Mok

Discipline

Psychologie (2)

Type de document

Articles (13) Recensions (3)

Co-auteur

Date

Source

Mot-clé

Treatment (12) Patients (12) Patients (12) Human beings (11) Lungs--Cancer (11) Cancer (11) Lungs (10) thérapie (9) Therapeutics (9) Use (8) survie (7) Survival (7) danger (6) maladie (6) procès (6) Inhibitors (6) maladie (6) Ci (Chinese poetry) (5) Confidence (5) Chemotherapy (5) temps (durée) (4) norme (4) sécurité (4) analyse (4) biomarqueur (4) taux (4) Testing (4) Chemotherapy (4) Time (4) Testing (4)

Documents écrit par T. Mok (13) | parle de T. Mok (0)

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
S. Peters et al.
NTRK gene fusion testing and management in lung cancer.
M. Repetto et al.
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
E.B. Garon et al.
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
J.R. Gosney et al.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
M.L. Johnson et al. (20 févr. 2023)
High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.
R. Dziadziuszko et al. (2023)
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
S. Peters et al.
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
R. Dziadziuszko et al. (2 mai 2022)
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology.
C. Gridelli et al.
The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective.
C. Sessa et al.
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
T. Mok et al.
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
S. Gadgeel et al. (1 nov. 2018)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
S. Peters et al. (31 août 2017)